Can A REMS Block A Generic? Thalomid Could Be Early Test
Executive Summary
Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product
You may also be interested in...
REMS Hurdles To Generic Entry: From Brand Access To Patent Claims
Can generic manufacturers use patented elements of a drug distribution plan? Will FDA accept an alternative REMS program? Will brand companies have to provide access to their products? As the number of brand products subject to REMS grows, so do the unanswered questions for generic firms.
Playing It Too Safe?: FTC Investigating Use Of REMS To Block Generics
The Federal Trade Commission is looking into whether companies are using their Risk Evaluation and Mitigation Strategies to thwart generic competition.
Playing It Too Safe?: FTC Investigating Use Of REMS To Block Generics
The Federal Trade Commission is looking into whether companies are using their Risk Evaluation and Mitigation Strategies to thwart generic competition.